The scientist’s investigation covers issues in Internal medicine, Chemotherapy, Surgery, Oncology and Cancer. In general Internal medicine, his work in Metastatic Urothelial Carcinoma, Clinical trial and Atezolizumab is often linked to In patient linking many areas of study. As part of the same scientific family, Dean F. Bajorin usually focuses on Chemotherapy, concentrating on Survival analysis and intersecting with Docetaxel, Gastroenterology and Vincristine.
Dean F. Bajorin has researched Surgery in several fields, including Carcinoma and Urology. His Oncology study combines topics in areas such as Germline mutation, Lynch syndrome, Targeted therapy, Toxicity and Immunotherapy. Dean F. Bajorin works on Cancer which deals in particular with Bladder cancer.
His primary areas of investigation include Internal medicine, Oncology, Chemotherapy, Surgery and Bladder cancer. His Cisplatin, Cancer, Germ cell tumors and Metastatic Urothelial Carcinoma study in the realm of Internal medicine connects with subjects such as In patient. His work in Oncology addresses subjects such as Pembrolizumab, which are connected to disciplines such as Vinflunine and Docetaxel.
His Chemotherapy study frequently links to related topics such as Urology. The study incorporates disciplines such as Transitional cell carcinoma and Carcinoma in addition to Surgery. His work deals with themes such as Cancer research and Clinical trial, which intersect with Bladder cancer.
His primary scientific interests are in Internal medicine, Oncology, Bladder cancer, Cancer research and Metastatic Urothelial Carcinoma. His research integrates issues of Germ cell tumors, Chemotherapy, Cisplatin and Cohort in his study of Oncology. His Chemotherapy research incorporates themes from Muscle invasive and Urology.
His Bladder cancer study incorporates themes from Neoadjuvant therapy, Clinical trial and Bacillus. In his research, DNA damage is intimately related to Gene, which falls under the overarching field of Cancer research. His studies deal with areas such as Gastroenterology, PD-L1, Biomarker and Clinical endpoint as well as Metastatic Urothelial Carcinoma.
Dean F. Bajorin mostly deals with Internal medicine, Oncology, Bladder cancer, Pembrolizumab and Chemotherapy. His research in Internal medicine focuses on subjects like Gastroenterology, which are connected to Antibody. His Oncology research includes themes of Survival rate, Cancer, Lynch syndrome and Cohort.
Dean F. Bajorin has included themes like Improved survival and Histology in his Cancer study. His study in Bladder cancer is interdisciplinary in nature, drawing from both Neoadjuvant therapy, Clinical trial and Dissection. He interconnects Cystectomy and Urology in the investigation of issues within Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden.
The Lancet (2016)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N Weinstein;Rehan Akbani;Bradley McIntosh Broom;Wenyi Wang.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet.
The New England Journal of Medicine (2017)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann.
Nature Genetics (2019)
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
GM Mead;SP Stenning;P Cook;SD Fossa.
Journal of Clinical Oncology (1997)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles.
The Lancet (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V Balar;Daniel Castellano;Peter H O'Donnell;Petros Grivas.
Lancet Oncology (2017)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.
Harry W. Herr;Bernard H. Bochner;Guido Dalbagni;S. Machele Donat.
The Journal of Urology (2002)
Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy
Dean F. Bajorin;Paul M. Dodd;Madhu Mazumdar;Melissa Fazzari.
Journal of Clinical Oncology (1999)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer;Gopa Iyer;Aphrothiti J. Hanrahan;Matthew Ivan Milowsky;Matthew Ivan Milowsky;Hikmat Al-Ahmadie.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: